Not enough safety and efficacy evidence for any of the experimental therapies for Ebola virus

By William Chin, PhD, Scientific Coordinator, EUCRAF

The European Medicines Agency (EMA) published an interim report on seven experimental medicines intended for the treatment of people infected with the Ebola virus. The observed findings showed that the data is highly variable and there is not enough safety and efficacy evidence for any of the experimental therapies for Ebola virus. The experimental medicines are:

1. BCX4430 (Biocryst);

2. Brincidofovir (Chimerix);

3. Favipiravir (Fujifilm Corporation/Toyama);

4. TKM-100802 (Tekmira);

5. AVI-7537 (Sarepta);

6. ZMapp (Leafbio Inc.);

7. Anti-Ebola F(ab’)2 (Fab’entech).

Source:

1. EMA Press Release, 16 Dec 2014, Experimental Ebola treatments still at early stage of development